NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis $9.39 0.00 (0.00%) As of 05/9/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avadel Pharmaceuticals Stock (NASDAQ:AVDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avadel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.32▼$9.6750-Day Range$6.59▼$9.4752-Week Range$6.38▼$17.51Volume1.36 million shsAverage Volume1.23 million shsMarket Capitalization$907.35 millionP/E RatioN/ADividend YieldN/APrice Target$19.43Consensus RatingBuy Company OverviewAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More… Avadel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreAVDL MarketRank™: Avadel Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 556th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 9.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.21% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.21% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.61 News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Avadel Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesAvadel Pharmaceuticals' (AVDL) Buy Rating Reiterated at Needham & Company LLCMay 10 at 2:21 AM | americanbankingnews.comAvadel Pharmaceuticals PLC (AVDL) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 8 at 4:34 AM | finance.yahoo.comThis next market event could mean total financial ruin for someYou think the volatility is over? Think again … Because it’s just getting started. In fact, according to a strange investment secret discovered just before the Great Depression …May 10, 2025 | Weiss Ratings (Ad)Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Up on Strong EarningsMay 8 at 2:13 AM | americanbankingnews.comAvadel Pharmaceuticals reports Q1 EPS (5c), consensus (7c)May 7 at 6:51 PM | msn.comAvadel Pharmaceuticals sees FY25 revenue $255M-$265M, consensus $249.16MMay 7 at 1:50 PM | msn.comAppeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fightMay 7 at 1:50 PM | finance.yahoo.comAvadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call TranscriptMay 7 at 1:19 PM | seekingalpha.comSee More Headlines AVDL Stock Analysis - Frequently Asked Questions How have AVDL shares performed this year? Avadel Pharmaceuticals' stock was trading at $10.51 at the start of the year. Since then, AVDL stock has decreased by 10.7% and is now trading at $9.39. View the best growth stocks for 2025 here. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The firm's revenue for the quarter was up 93.2% compared to the same quarter last year. Read the conference call transcript. Who are Avadel Pharmaceuticals' major shareholders? Top institutional investors of Avadel Pharmaceuticals include Vanguard Group Inc. (4.04%), Wealth Effects LLC (2.45%), Modera Wealth Management LLC (0.58%) and Deutsche Bank AG (0.52%). Insiders that own company stock include Eric J Ende, Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX). Company Calendar Last Earnings5/07/2025Today5/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVDL CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees70Year Founded2015Price Target and Rating Average Stock Price Target$19.43 High Stock Price Target$30.00 Low Stock Price Target$12.00 Potential Upside/Downside+106.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-52.53% Pretax Margin-52.84% Return on Equity-93.34% Return on Assets-44.77% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.60 Sales & Book Value Annual Sales$169.12 million Price / Sales5.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book9.58Miscellaneous Outstanding Shares96,629,000Free Float91,737,000Market Cap$907.35 million OptionableOptionable Beta1.40 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:AVDL) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.